ASX:Live
Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Valuation
Value
Consensus
Momentum
Price
Weak
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Telephone
61.3.9123.1140
Address
Level 5 90 William Street Melbourne, Victoria (VIC) 3000
Description
Amplia Therapeutics Ltd. is a medical biotechnology company, which engages in the development of drugs for potential use in multiple indications including oncology and chronic fibrosis. Its immuno-modulator microparticles technology can be used to induce the human immune system to fight certain cancers and infections, or modulate certain immune mechanisms implicated in autoimmune diseases such as multiple sclerosis. The company was founded by Christopher J. Burns on May 31, 2000 and is headquartered in Melbourne, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.05 - 0.43
Trade Value (12mth)
AU$113,100.00
1 week
5.26%
1 month
-29.82%
YTD
115.05%
1 year
56.97%
All time high
15.95
EPS 3 yr Growth
-10.50%
EBITDA Margin
N/A
Operating Cashflow
-$7m
Free Cash Flow Return
-42.40%
ROIC
-40.50%
Interest Coverage
-187.70
Quick Ratio
7.90
Shares on Issue (Fully Dilluted)
365m
HALO Sector
Healthcare
Next Company Report Date
01-Jun-26
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
| Date | Announcements |
|---|---|
|
07 August 25 |
Presentation - Targeting Pancreatic Cancer and Beyond
×
Presentation - Targeting Pancreatic Cancer and Beyond |
|
06 August 25 |
Positive ACCENT Trial Topline Data Released
×
Positive ACCENT Trial Topline Data Released |
|
01 August 25 |
Change of Registered Office and Principal Place of Business
×
Change of Registered Office and Principal Place of Business |
|
01 August 25 |
Share Purchase Plan Prospectus
×
Share Purchase Plan Prospectus |
|
31 July 25 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
|
30 July 25 |
Australian Ethics Clearance for Pancreatic Cancer Trial
×
Australian Ethics Clearance for Pancreatic Cancer Trial |
|
30 July 25 |
Change in substantial holding
×
Change in substantial holding |
|
30 July 25 |
Change in substantial holding
×
Change in substantial holding |
|
30 July 25 |
Ceasing to be a substantial holder - Blueflag Holdings
×
Ceasing to be a substantial holder - Blueflag Holdings |
|
29 July 25 |
Application for quotation of securities - ATX
×
Application for quotation of securities - ATX |
|
29 July 25 |
Notice under Section 708A(5)(e) of the Corporations Act
×
Notice under Section 708A(5)(e) of the Corporations Act |
|
25 July 25 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
|
23 July 25 |
Amplia announces A$25m Placement and Launches A$2.5m SPP
×
Amplia announces A$25m Placement and Launches A$2.5m SPP |
|
23 July 25 |
Proposed issue of securities - ATX
×
Proposed issue of securities - ATX |
|
23 July 25 |
Proposed issue of securities - ATX
×
Proposed issue of securities - ATX |
|
23 July 25 |
Proposed issue of securities - ATX
×
Proposed issue of securities - ATX |
|
23 July 25 |
Capital Raising Presentation
×
Capital Raising Presentation |
|
23 July 25 |
Application for quotation of securities - ATX
×
Application for quotation of securities - ATX |
|
23 July 25 |
Notice under Section 708A(5)(e) of the Corporations Act
×
Notice under Section 708A(5)(e) of the Corporations Act |
|
21 July 25 |
Trading Halt
×
Trading Halt |
|
11 July 25 |
Another Partial Response in ACCENT Pancreatic Cancer Trial
×
Another Partial Response in ACCENT Pancreatic Cancer Trial |
|
04 July 25 |
Application for quotation of securities - ATX
×
Application for quotation of securities - ATX |
|
02 July 25 |
Additional Partial Response in Pancreatic Cancer Trial
×
Additional Partial Response in Pancreatic Cancer Trial |
|
02 July 25 |
Annual General Meeting to be held Wednesday 27 August 2025
×
Annual General Meeting to be held Wednesday 27 August 2025 |
|
24 June 25 |
Amplia Gains US Ethics Approval for Pancreatic Cancer Trial
×
Amplia Gains US Ethics Approval for Pancreatic Cancer Trial |
Load More
Load Less
Ex Dividend Date (est.)
DIV Yield
Franking Level
DPSg
Quality Yield
Falling Divs over next 2
Consensus Score
Recommendation
EPS 1 month Change
Quality Yield
Falling Divs over next 2
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
.svg)
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.
